A new research project 'Artifcial Intelligence for treating cancer therapy resistance (AI-Care)' has been evaluated successfully by Carl-Zeiss-Stiftung. The AI-Care project, a collaborative effort between RPTU, DKFZ, and the University of Heidelberg, aims to unravel the fundamental principles underlying cancer cell plasticity and devise personalized therapeutic strategies that overcome the emergence of resistance.

Glioblastomas are aggressive brain tumors characterized by a high degree of phenotypic heterogeneity and plasticity. Their ability to switch to resistant cell states renders conventional therapies ineffective. The goal of this project is to decipher the cancer plasticity code of glioblastoma using state-of-the-art AI and optimization techniques that characterize the drug response dynamics of glioblastoma. Our research aims for breakthroughs in understanding the biological basis of cancer plasticity and the development of personalized therapeutic treatments, tailored to each patient's unique characteristics to significantly improve outcomes and reduce the emergence of resistance. The project team's work has the potential to break new ground not only in the treatment of glioblastoma, but also in the treatment of other deadly cancers. The concept of AI-based personalized precision medicine may become a reality in the medium term.

Stay tuned for more updates on this innovative project as we work towards advancing our understanding of cancer and improving treatment outcomes. We are grateful for the support and opportunity provided by Carl-Zeiss-Stiftung, and we are excited to make a positive impact in the field of oncology.

Checkout the news on LinkedIn and press release by Carl-Zeiss-Stiftung.